Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
BACKGROUND
Bisphosphonates are the standard of care for treating and preventing the complications of bone metastases. Ibandronic acid is available in effective and well-tolerated oral (50 mg daily) and intravenous (6 mg via > or = 15 min infusion every 3-4 weeks) formulations.


OBJECTIVE
This paper reviews the latest preclinical and clinical data supporting the use of ibandronic acid for the prevention and treatment of the skeletal complications of neoplastic bone disease, focusing on metastatic breast cancer. The aim was to update a review of ibandronic acid published in 2004 by the current author.


CONCLUSIONS
Ibandronate remains the only bisphosphonate with approved oral and intravenous formulations; ibandronate should be considered when designing a bisphosphonate-containing regimen for patients with bone metastases from breast cancer.
Pecherstorfer
Martin
M
Hematologic-Oncologic Service, Landeklinikum Krems, Mitterweg 10, A-3500 Krems, Austria. martin.pecherstorfer@krems.lknoe.at
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D006801:Humans; D000077557:Ibandronic Acid; D010146:Pain / Q000188:drug therapy
D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077557:Ibandronic Acid